Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.33 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.33 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.33 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | BMP1 | P13497 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | CPA1 | P15085 | 1/20 | 0.32 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.32 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20131933 | 0.81 | MMP1 (0.36) | FOLH1GLO1NAALAD2RIMKLAKEAP1 | |
| SCHEMBL21074906 | 0.76 | PSMB5 (0.46) | FOLH1NAALAD2RIMKLABMP1 | |
| SCHEMBL25129089 | 0.76 | FOLH1 (0.38) | FOLH1NAALAD2RIMKLABMP1 | |
| SCHEMBL21305826 | 0.71 | MMP1 (0.36) | FOLH1GLO1NAALAD2RIMKLAKEAP1 | |
| SCHEMBL23685503 | 0.70 | TERT (0.45) | GLO1MMEACECPA1ACE2 | |
| SCHEMBL25448154 | 0.70 | GLO1 (0.40) | GLO1KEAP1BMP1PTGS1GSTK1 | |
| SCHEMBL14113357 | 0.69 | LMNA (0.42) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL24622679 | 0.69 | FOLH1 (0.35) | FOLH1NAALAD2RIMKLAKEAP1BMP1 | |
| SCHEMBL19681930 | 0.69 | BMP1 (0.39) | FOLH1GLO1NAALAD2RIMKLAKEAP1 | |
| SCHEMBL27323792 | 0.69 | MMP1 (0.37) | GLO1KEAP1BMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180126000-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | ABBVIE INC. (US) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180126000-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | NR3C1, NR3C2, MC2R | FOLH1 1753/4885GLO1 1242/4885NAALAD2 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.